| Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure S Arends, L de Wolff, JF van Nimwegen, GMPJ Verstappen, J Vehof, ... The Lancet Rheumatology 3 (8), e553-e562, 2021 | 59 | 2021 |
| Ten years of the ESSDAI: is it fit for purpose? L de Wolff, S Arends, JF van Nimwegen, H Bootsma Clinical and Experimental Rheumatology 38 (4), 283-290, 2020 | 38 | 2020 |
| Long-term abatacept treatment for 48 weeks in patients with primary sjögren's syndrome: The open-label extension phase of the ASAP-III trial L de Wolff, JF van Nimwegen, E Mossel, GS van Zuiden, AJ Stel, ... Seminars in Arthritis and Rheumatism 53, 151955, 2022 | 28 | 2022 |
| Differences in presentation between paediatric-and adult-onset primary Sjögren's syndrome patients GE Legger, MB Erdtsieck, L de Wolff, AJ Stel, L Los, GM Verstappen, ... Clinical and Experimental Rheumatology 39 (6, Suppl. 133), S85-S92, 2021 | 13 | 2021 |
| Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren’s syndrome GM Verstappen, L de Wolff, S Arends, HM Heiermann, Y van Sleen, ... RMD open 8 (1), e002265, 2022 | 12 | 2022 |
| Serum and Tissue Biomarkers Associated With Composite of Relevant Endpoints for Sjögren Syndrome (CRESS) and Sjögren Tool for Assessing Response (STAR) to B Cell–Targeted … E Pontarini, E Sciacca, F Chowdhury, S Grigoriadou, F Rivellese, ... Arthritis & Rheumatology 76 (5), 763-776, 2024 | 10* | 2024 |
| Why do drug treatments fail in Sjögren’s disease? Considerations for treatment, trial design and interpretation of clinical efficacy S Arends, GM Verstappen, L de Wolff, S Pringle, FGM Kroese, A Vissink, ... Expert review of clinical immunology 19 (10), 1187-1194, 2023 | 8 | 2023 |
| Association of Circulating Antibody‐Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome TD Steinmetz, GM Verstappen, SR Schulz, L de Wolff, R Wilbrink, A Visser, ... Arthritis & Rheumatology 75 (6), 973-983, 2023 | 8 | 2023 |
| Patient Acceptable Symptom State (PASS) in patients with primary Sjögren's syndrome in daily clinical practice L de Wolff, A Vissink, JF van Nimwegen, G van Zuiden, E Mossel, L Olie, ... Clinical and Experimental Rheumatology 40 (12), 2303-2309, 2022 | 8 | 2022 |
| Selection of study endpoints and patients for clinical trials in primary Sjögren's syndrome S Arends, L de Wolff, L Deroo, GM Verstappen, A Vissink, FGM Kroese, ... Clinical and experimental rheumatology 40 (12), 2225-2232, 2022 | 8 | 2022 |
| Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary … L de Wolff, S Arends, P Pontarini, M Bombardieri, SJ Bowman, H Bootsma Clinical and Experimental Rheumatology 39 (6), S100-S106, 2021 | 8 | 2021 |
| Clinical determinants of vaginal dryness in patients with primary Sjögren's syndrome CA Farenhorst, L de Wolff, S Arends, JF van Nimwegen, FGM Kroese, ... Clinical and Experimental Rheumatology 39 (6), S73-S79, 2021 | 7 | 2021 |
| Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome N Inanc, B Kostov, R Priori, A Flores-Chavez, F Carubbi, A Szántó, ... Clinical and experimental rheumatology 40 (12), 2290-2297, 2022 | 4 | 2022 |
| Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren’s syndrome patients TD Steinmetz, L de Wolff, JH Terpstra, A Visser, H Bootsma, FGM Kroese, ... Clinical and Experimental Rheumatology 40 (12), 2338-2343, 2022 | 4 | 2022 |
| POS0193 evaluation of cress in the phase 2 randomised placebo-controlled study of sequential belimumab/rituximab administration in patients with primary Sjögren’s syndrome H Bootsma, S Arends, L De Wolff, KL Clark, A van Maurik, P Mistry, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 329-330, 2022 | 3 | 2022 |
| Minimal added value of separate dryness assessments compared with overall dryness in ESSPRI in patients with Sjögren’s disease L de Wolff, S Arends, GM Verstappen, H Bootsma Rheumatology 63 (2), e29-e31, 2024 | 2 | 2024 |
| Longitudinal evaluation of major salivary gland functioning in Sjogren’s disease patients in a prospective standard-of-care cohort NRF Sluijpers, K Delli, L De Wolff, AJ Stel, FKL Spijkervet, FGM Kroese, ... Clin. Exp. Rheumatol 41, 2474-2483, 2023 | 2 | 2023 |
| POS0145 CLINICAL RESPONSE TO RITUXIMAB IS ASSOCIATED WITH PREVENTION OF B-CELL DRIVEN SALIVARY GLAND INFLAMMATION AND EPITHELIAL RESTORATION AS REVEALED BY MOLECULAR PATHOLOGY … E Pontarini, F Chowdhury, E Sciacca, S Grigoriadou, W Murray-Brown, ... Annals of the Rheumatic Diseases 81 (Suppl 1), 299-300, 2022 | 2 | 2022 |
| OP0130 COMPOSITE OF RELEVANT ENDPOINTS IN SJÖGREN’S SYNDROME (CRESS): A COMPREHENSIVE TOOL FOR CLINICAL TRIALS S Arends, L de Wolff, JF Van Nimwegen, GM Verstappen, J Vehof, ... Annals of the Rheumatic Diseases 80 (Suppl 1), 74-75, 2021 | 2 | 2021 |
| Added value of the salivary gland ultrasonography OMERACT score in the ACR/EULAR classification criteria for Sjögren's disease D Rebel, L de Wolff, K Delli, AJ Stel, HC Kokol, A Vissink, FGM Kroese, ... Seminars in Arthritis and Rheumatism 67, 152473, 2024 | 1 | 2024 |
